Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 9/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895725 | 0.93 | MAPT (0.47) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL1007958 | 0.89 | MAPT (0.50) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL1007964 | 0.85 | MAPT (0.52) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL1008079 | 0.82 | MAPT (0.50) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL1896530 | 0.81 | MAPT (0.69) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL1007251 | 0.81 | MAPT (0.71) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL8000803 | 0.80 | MAPT (0.52) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL1008205 | 0.79 | LMNA (0.56) | POLBLMNA | |
| SCHEMBL1006951 | 0.78 | MAPT (0.52) | MAPTTP53THRBPOLBLMNA | |
| SCHEMBL1007250 | 0.76 | MAPT (0.52) | MAPTTP53THRBPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009119088-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | MAPT 4623/4885TP53 3973/4885THRB 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.